A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembrolizumab + Chemotherapy for Frontline Therapy of Metastatic, PD-L1+ Triple-Negative Breast Cancer (TNBC) in HLA-A2-Positive Patients
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Pembrolizumab (Primary) ; PVX 410 (Primary) ; Antineoplastics
- Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors OncoPep
- 18 Apr 2022 Planned initiation date changed from 1 Nov 2021 to 1 Apr 2022.
- 07 Sep 2021 Planned initiation date changed from 1 Apr 2021 to 1 Nov 2021.
- 24 Nov 2020 New trial record